Emad A. Rakha

35.0k total citations · 5 hit papers
494 papers, 20.5k citations indexed

About

Emad A. Rakha is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Emad A. Rakha has authored 494 papers receiving a total of 20.5k indexed citations (citations by other indexed papers that have themselves been cited), including 268 papers in Cancer Research, 264 papers in Oncology and 194 papers in Molecular Biology. Recurrent topics in Emad A. Rakha's work include Breast Cancer Treatment Studies (198 papers), Breast Lesions and Carcinomas (116 papers) and HER2/EGFR in Cancer Research (87 papers). Emad A. Rakha is often cited by papers focused on Breast Cancer Treatment Studies (198 papers), Breast Lesions and Carcinomas (116 papers) and HER2/EGFR in Cancer Research (87 papers). Emad A. Rakha collaborates with scholars based in United Kingdom, United States and Egypt. Emad A. Rakha's co-authors include Ian O. Ellis, Andrew R. Green, Jorge S. Reis‐Filho, Andrew H.S. Lee, Maysa E. El‐Sayed, Mohammed A. Aleskandarany, J.F.R. Robertson, Graham Ball, Michael S. Toss and Claire E. Paish and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Emad A. Rakha

480 papers receiving 20.1k citations

Hit Papers

Prognostic markers in triple‐negative breast cancer 2006 2026 2012 2019 2006 2008 2010 2010 2022 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prognostic markers in triple‐negative breast cancer
    2006 1.0k citations Emad A. Rakha, Andrew R. Green et al. profile →
  2. Basal-Like Breast Cancer: A Critical Review
    2008 691 citations Emad A. Rakha, Ian O. Ellis et al. profile →
  3. Breast cancer prognostic classification in the molecular era: the role of histological grade
    2010 648 citations Emad A. Rakha, Ian O. Ellis et al. Breast Cancer Research profile →
  4. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists
    2010 506 citations Emad A. Rakha, Ian O. Ellis et al. Modern Pathology profile →
  5. Breast tumor microenvironment structures are associated with genomic features and clinical outcome
    2022 141 citations Elena Provenzano, Andrew R. Green et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emad A. Rakha United Kingdom 68 9.4k 9.4k 8.1k 4.2k 2.7k 494 20.5k
Sunil R. Lakhani Australia 71 7.1k 0.8× 8.2k 0.9× 6.8k 0.8× 5.0k 1.2× 2.3k 0.9× 302 18.7k
Britta Weigelt United States 70 8.1k 0.9× 8.4k 0.9× 7.8k 1.0× 3.5k 0.8× 3.0k 1.1× 311 19.1k
Edi Brogi United States 55 5.6k 0.6× 5.4k 0.6× 6.0k 0.8× 2.7k 0.6× 2.1k 0.8× 237 15.8k
W. Fraser Symmans United States 78 14.5k 1.5× 14.3k 1.5× 8.2k 1.0× 4.6k 1.1× 3.9k 1.5× 323 25.7k
Ayşegül A. Şahin United States 87 12.1k 1.3× 10.2k 1.1× 9.0k 1.1× 5.7k 1.4× 3.2k 1.2× 389 25.3k
Maggie C.U. Cheang United States 47 12.6k 1.3× 12.4k 1.3× 7.4k 0.9× 3.4k 0.8× 4.0k 1.5× 122 21.3k
Lars A. Akslen Norway 67 14.0k 1.5× 11.6k 1.2× 13.8k 1.7× 3.3k 0.8× 4.4k 1.7× 314 29.1k
Jonas Bergh Sweden 73 15.6k 1.7× 11.6k 1.2× 11.2k 1.4× 2.8k 0.7× 4.9k 1.9× 521 29.1k
Torsten O. Nielsen Canada 77 16.1k 1.7× 14.5k 1.5× 10.3k 1.3× 4.9k 1.2× 7.7k 2.9× 241 31.1k
Stefanie S. Jeffrey United States 51 13.8k 1.5× 14.9k 1.6× 16.6k 2.1× 4.2k 1.0× 3.9k 1.5× 138 33.6k

Countries citing papers authored by Emad A. Rakha

Since Specialization
Citations

This map shows the geographic impact of Emad A. Rakha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emad A. Rakha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emad A. Rakha more than expected).

Fields of papers citing papers by Emad A. Rakha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emad A. Rakha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emad A. Rakha. The network helps show where Emad A. Rakha may publish in the future.

Co-authorship network of co-authors of Emad A. Rakha

This figure shows the co-authorship network connecting the top 25 collaborators of Emad A. Rakha. A scholar is included among the top collaborators of Emad A. Rakha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emad A. Rakha. Emad A. Rakha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rakha, Emad A., Fayaz Malik, Mayank Singh, et al.. (2025). Human papilloma virus (HPV) mediated cancers: an insightful update. Journal of Translational Medicine. 23(1). 483–483. 12 indexed citations
2.
Coombes, R. Charles, William E. Hart, Darius Francescatti, et al.. (2024). Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study. Breast Cancer Research and Treatment. 205(2). 349–358. 3 indexed citations
3.
Lashen, Ayat, Michael S. Toss, Islam M. Miligy, et al.. (2024). Nottingham prognostic x (NPx): a risk stratification tool in ER‐positive HER2‐negative breast cancer: a validation study. Histopathology. 85(3). 468–477. 1 indexed citations
4.
5.
Ibrahim, Asmaa, et al.. (2023). Novel 2 Gene Signatures Associated With Breast Cancer Proliferation: Insights From Predictive Differential Gene Expression Analysis. Modern Pathology. 37(2). 100403–100403. 4 indexed citations
6.
Quinn, Cecily, Michael S. Toss, Mansour Alsaleem, et al.. (2023). Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance. European Journal of Cancer. 197. 113473–113473. 6 indexed citations
7.
Katayama, Ayaka, Jane Starczynski, Michael S. Toss, et al.. (2022). The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry‐equivocal invasive breast cancer. Histopathology. 81(4). 511–519. 2 indexed citations
8.
Kurozumi, Sasagu, Kyoichi Kaira, Hiroshi Matsumoto, et al.. (2022). Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Scientific Reports. 12(1). 2742–2742. 29 indexed citations
9.
Rakha, Emad A., et al.. (2022). Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates. Pathobiology. 89(5). 263–277. 18 indexed citations
10.
Shiino, Sho, Graham Ball, Binafsha Manzoor Syed, et al.. (2021). Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. Breast Cancer Research and Treatment. 191(1). 1–14. 12 indexed citations
11.
Joseph, Chitra, et al.. (2020). Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Research and Treatment. 181(3). 541–551. 21 indexed citations
12.
Browning, Lisa, Richard Colling, Emad A. Rakha, et al.. (2020). Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective. Journal of Clinical Pathology. 74(7). 443–447. 49 indexed citations
13.
Pu, Xuan, Sarah J. Storr, Emad A. Rakha, et al.. (2018). High nuclear MSK1 is associated with longer survival in breast cancer patients. Journal of Cancer Research and Clinical Oncology. 144(3). 509–517. 13 indexed citations
14.
Rakha, Emad A. & Andrew R. Green. (2016). Molecular classification of breast cancer: what the pathologist needs to know. Pathology. 49(2). 111–119. 92 indexed citations
15.
Bartlett, John M.S., Daniel Rea, Sarah E. Pinder, et al.. (2016). Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right. European Journal of Surgical Oncology. 42(7). 994–998. 4 indexed citations
16.
Aleskandarany, Mohammed A., Ola H. Negm, Andrew R. Green, et al.. (2014). Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Research and Treatment. 145(2). 339–348. 57 indexed citations
17.
Barros, F., Tarek M.A. Abdel-Fatah, Paul M. Moseley, et al.. (2014). Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast Cancer Research and Treatment. 144(2). 273–285. 16 indexed citations
18.
Powe, Desmond G., Hany Onsy Habashy, Tarek M.A. Abdel-Fatah, et al.. (2009). Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. Breast Cancer Research. 11(6). R90–R90. 38 indexed citations
19.
Taneja, Sangeeta, Andrew Evans, Emad A. Rakha, et al.. (2008). The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. Clinical Radiology. 63(11). 1228–1235. 31 indexed citations
20.
Kurien, Thomas, Emma C. Paish, J Ronan, et al.. (2005). Three dimensional reconstruction of a human breast carcinoma using routine laboratory equipment and immunohistochemistry. Journal of Clinical Pathology. 58(9). 968–972. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sunil R. Lakhani Breakdown of academic impact, for papers by Britta Weigelt Breakdown of academic impact, for papers by Edi Brogi Breakdown of academic impact, for papers by W. Fraser Symmans Breakdown of academic impact, for papers by Ayşegül A. Şahin Breakdown of academic impact, for papers by Maggie C.U. Cheang Breakdown of academic impact, for papers by Lars A. Akslen Breakdown of academic impact, for papers by Jonas Bergh Breakdown of academic impact, for papers by Torsten O. Nielsen Breakdown of academic impact, for papers by Stefanie S. Jeffrey
Rankless by CCL
2026